Oxford Pharm Gp Share Discussion Threads

[cheshire man] 05/3/2015 13:43

Maybe Neil Woodford topping up :-)

[l0wrdr] 05/3/2015 13:38

Big buyer in the wings here by the looks of it

[fillipe] 05/3/2015 13:32

Mmmm....might be leaving the 7p's behind and seeing the 8p's.

Still cheap as particularly so if N+1 Singer reiterate their last and very recent CORP of 2015 eps at 1.4p

f

[barcelona111] 05/3/2015 13:07

Yes finally people realising the potential here,been invested since 2011 long way to go yet,
Remember management options 10p/20p/50p!!

[cheshire man] 05/3/2015 13:03

Delighted with this move up, have held from the lows, always felt it would repay me :-)

[hjfe] 05/3/2015 13:01

Great opportunity here - MMs want this up up up

[hjfe] 05/3/2015 12:52

Bid moving up without any trade - MMs clearly want to re-rate this.

[hjfe] 05/3/2015 12:43

Should see a sustained breakout now from this level - plenty of newsflow to come.

[fillipe] 05/3/2015 12:40

Good to see that both the bid/ask prices are now starting with 7.

f

[fillipe] 05/3/2015 10:23

Gradual upticks today, on each buy. Best ask now 6.9p, but only 50k showing for that. Highest ask is now up at 7.2p but that could all easily ratchet up as total ask currently only 300,000 shrs .

6.9p been paid, as I type.

OXP looking solidly good.

f

[timbo003] 05/3/2015 07:34

I'm surprised there are no comments from the usually vociferous shareholders here, so here are my observations:

* The data regarding what heathcare providers might be prepared to pay is new and interesting (i.e. $2/day vs $0.4 per day)

* Needless to say they underplay the fact that the first POC study in man for Ibuprofen didn't meet all its end points

* I thought that they decided to put the emphasis on safer rather than taste masked after the animal studies, not after their POC in healthy volunteers?

* Sales in the Calcium product down 25%, but no real explanation why.

* The clinical programs for the POC studies for Naproxwn and Ibuprofen are as previously stated and on track (Naproxyn PK data due before end of March).

* Emphasis on Rx opportunity rather than OTC opportunities (a wise decision IMO)

* Still progressing diclofenac and aspirin, statins on the back burner.

I suspect they will mark the shares up today following this, largely in anticipation of the PK data from the Naproxen POC results later this month.

[fillipe] 04/3/2015 16:20

Finals cnfmd for tomorrow, 5th Mar.

Their "Outlook" statement should be very interesting!

f

[fillipe] 03/3/2015 10:41

eps 1.4p for 2015 also at 2-3-2015.

Finals for 2014 due any day, so maybe a clue about 2015 then.

f

[fillipe] 28/2/2015 18:05

2015 forecast eps 1.4p. I had wondered if last month might have been an unusual typo, but now see that 27-2-2015, N+1 Singer reiterate.

Seems like a 6p share price is looking pretty damn cheap.

f

[fillipe] 18/2/2015 14:50

Yes, your right - hopefully not there for long.

[gnnmartin] 18/2/2015 11:11

A lot of selling at 6p and no further share price weakness. That suggests to me that there is a buyer behind scenes at (say) 6.1p.

[fillipe] 14/2/2015 15:21

A very small bit of profit taking ahead of the weekend, all after a healthy rise.

[saturn5] 13/2/2015 19:13

Just my luck when I bought some at 6.7

[burbelly] 13/2/2015 18:12

Maybe a little profit taken? Been quite a rise

[saturn5] 13/2/2015 17:09

why the sudden drop ?

[fillipe] 12/2/2015 17:30

Just a reminder that at 22-10-2014 almost 76% of the company's shares were held by the "over 3%" shareholders. I think that since that date the figure is a bit higher.

f

[burbelly] 12/2/2015 16:46

Has no interest in making money either been bashing since 2p